Arginine-rich cell-penetrating peptides can efficiently cross cell membranes and deliver drugs, nucleic acids, and other molecules directly into cancer cells while escaping degradation.
Dual function: membrane crossing + endosome escapeArginine-rich CPPs are uniquely effective because their guanidinium groups enable efficient membrane crossing while also disrupting endosomal membranes to prevent degradation of delivered cargo.
What the researchers found
Arginine-rich cell-penetrating peptides exhibit higher transmembrane efficiency compared to other CPP types due to bidentate bonding between the guanidinium groups of arginine residues and negatively charged components on cell surfaces. This creates a particularly strong and specific interaction with cell membranes.
A second critical function is endosome escape: when peptides are taken up by cells through endocytosis, they typically become trapped in endosomes that eventually fuse with lysosomes for degradation. Arginine-rich CPPs can disrupt endosomal membranes, allowing the delivered cargo — drugs, nucleic acids, or macromolecules — to escape into the cytoplasm where it can exert its therapeutic effect.
Why it matters
Many potent anticancer drugs and therapeutic nucleic acids fail in the clinic because they can't cross cell membranes to reach their intracellular targets. Cell-penetrating peptides solve this fundamental delivery problem. Arginine-rich CPPs are among the most promising because they combine two essential functions: efficient membrane crossing and endosome escape. Understanding their design principles enables the development of more effective drug delivery systems for cancer and potentially other diseases.
How the study worked
This is a review article summarizing 30 years of research on arginine-rich cell-penetrating peptides. The review covers the biological properties, design principles, membrane penetration mechanisms (including the role of guanidinium-membrane interactions), endosome escape mechanisms, and biomedical applications in cancer drug delivery and tumor biosensing.
What this study cannot tell us
As a review article, this paper synthesizes existing research without presenting new data. Many CPP applications described remain at the preclinical stage. Key challenges not fully resolved include CPP selectivity (they can enter both healthy and cancer cells), potential toxicity at high concentrations, and the complexity of translating in vitro membrane penetration into effective in vivo tumor delivery. The review focuses on arginine-rich CPPs and may not capture the full landscape of CPP diversity.
How to read the evidence
This is a narrative review summarizing 30 years of CPP research. While it provides a comprehensive overview, the individual studies reviewed range from basic biophysics to early-stage preclinical work. No clinical trial data for arginine-rich CPP-based cancer therapies is presented.
When this study was published
Published in 2025 (online 2023), this review captures the current state of arginine-rich CPP research and recent advances in their application to cancer drug delivery.
The bigger picture
Cell-penetrating peptides represent one of the most versatile drug delivery platforms in biomedical research. The field began with the discovery that the HIV Tat protein could cross cell membranes, and has since expanded to include numerous natural and synthetic CPP sequences. Arginine-rich CPPs are now being incorporated into nanoparticle systems, antibody-drug conjugates, and gene therapy vectors. As cancer treatment moves increasingly toward intracellular targets (transcription factors, epigenetic regulators, non-coding RNAs), the ability to efficiently deliver cargo across cell membranes becomes even more critical.
Questions still open
- How can arginine-rich CPPs be engineered for tumor-selective delivery, avoiding uptake by healthy cells?
- What is the optimal CPP design for delivering specific cargo types (small molecules vs. proteins vs. nucleic acids)?
- Can CPP-based delivery systems overcome the barriers to clinical translation that have limited their approval as drugs?
Common questions
What are cell-penetrating peptides and how do they deliver drugs?
Why is endosome escape important for drug delivery?
Read the original research
Biological Properties of Arginine-rich Peptides and their Application in Cargo Delivery to Cancer.
Current drug delivery, 22(4), 387-400
Citation
Ma, Minghai; Zhao, Ruizhao; Li, Xing; Jing, Minxuan; Song, Rundong; Fan, Jinhai. (2025). Biological Properties of Arginine-rich Peptides and their Application in Cargo Delivery to Cancer.. Current drug delivery, 22(4), 387-400. https://doi.org/10.2174/1567201820666230417083350